Craig-Hallum initiated coverage of Biodesix with a Buy rating and $3 price target. Biodesix is a leading provider of blood-based, diagnostic tests for lung cancer risk assessment, the analyst tells investors in a research note. The firm expects these tests could eventually become the standard of care for lung-cancer risk assessment, representing a $4.5B opportunity. It believes Biodesix could be the beginning of a “substantial” product adoption curve, with sustainable 25%-plus revenue growth and a clear path to profitability.